OP0257 RISK OF HAEMATOLOGICAL MALIGNANCY IN PATIENTS WITH PSORIATIC ARTHRITIS, OVERALL AND IN RELATION TO TNF INHIBITORS - A NORDIC COHORT STUDY

Background Several autoimmune inflammatory diseases, including rheumatoid arthritis (RA), are associated with increased risk of malignant lymphomas. There is also a longstanding concern lymphoma development tumour necrosis factor inhibitor (TNFi) treatment, but most studies in RA to date do not indicate an additionally risk. Corresponding psoriatic (PsA), both respect the underlying risks, and risks relation treatment TNFi, limited. Data on myeloid malignancies PsA scarce. Objectives To estimate haematological malignancy overall by lymphoid types TNFi treated versus (vs.) biologics-naïve patients across five Nordic countries. Additionally, we investigated as compared general population. Methods We identified starting first ever from clinical rheumatology registers (CRR) Sweden (SE), Denmark (DK), Norway (NO), Finland (FI), Iceland (ICE) 2006 through 2019 (n=10 621). a) CRR (n=18 705, all countries) b) national patient (NPR, n=27 286, SE DK only). PsA, randomly sampled population comparators matched year birth, sex, calendar at start follow-up, PsA. Through linkage mandatory cancer countries, collected information overall, categorised into or types. By applying modified Poisson regression, estimated pooled incidence rate ratio (IRR) 95% confidence intervals (CI) for vs. population, adjusted age (18-55, 56-65, 66-70, >70 years), period (2006-2010, 2011-2019) country, using robust standard errors. Results observed 40 events (during 59 827 person-years) among resulting crude (IR) 67 per 100 000 person-years. The corresponding IR was 91 (63 events) CRR, 118 (172 NPR. This resulted IRR 0.97 (0.69 1.37) TNFi-treated 0.84 (0.64 1.10) 1.35 (1.17 1.55). Throughout, estimates were largely similar (Figure 1). substantially akin different agents. Figure 1. Pooled ratios (IRRs) (95% CI) types, comparators. Legend: Lymphoid include international classification diseases (ICD) 10 codes C81-86, C88, C90-91. Myeloid ICD10 C92-95, D45-D46, D47.1, D47.3-5. Incidence Conclusion In this large five-country cohort study, did observe any nor TNFi. contrast, there signals moderately malignancies, findings importance perspective. Acknowledgements would like acknowledge NordForsk FOREUM, especially representatives collaboration their valuable contribution study. Disclosure Interests René Cordtz: None declared, Johan Askling Consultant of: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, UCB, Grant/research support from: Bénédicte Delcoigne: Karin Ekström Smedby: Eva Baecklund: Christine Ballegaard: Pia Isomäki Speakers bureau: AbbVie, Lilly Roche ViforPharma, Kalle Aaltonen: Björn Gudbjornsson Novartis, related work, Thorvardur Love Celgene, Sella Aa. Provan: Brigitte Michelsen Joe Sexton: Lene Dreyer Galderma Janssen, BMS Hellgren: declared